RenovoRx (RNXT) announces that Northwell Health Cancer Institute (NHCI) has joined its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoRx's TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, comparing intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath system to standard intravenous chemotherapy. NHCI joins other U.S. clinical sites in the study, which aims to complete enrollment in the first half of 2025.
the first half of 2025.
